scispace - formally typeset
F

F. Ivy Carroll

Researcher at Research Triangle Park

Publications -  301
Citations -  11139

F. Ivy Carroll is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Nicotinic agonist & Dopamine transporter. The author has an hindex of 52, co-authored 301 publications receiving 10411 citations. Previous affiliations of F. Ivy Carroll include RTI International & St. Joseph's Hospital and Medical Center.

Papers
More filters
Journal ArticleDOI

Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.

TL;DR: In vitro methods determined the neurochemical mechanism of action of amphetamine, 3,4‐methylenedioxymethamphetamine (MDMA), (+)‐methamphetamine, ephedrine, phentermine, and aminorex, and demonstrated that the most potent effect of these stimulants is to release NE.
Journal ArticleDOI

Structure of the human κ-opioid receptor in complex with JDTic

TL;DR: Analysis of site-directed mutagenesis and ligand structure–activity relationships confirms the interactions observed in the crystal structure, thereby providing a molecular explanation for κ-OR subtype selectivity, and essential insights for the design of compounds with new pharmacological properties targeting the human λ-OR.
Journal ArticleDOI

Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors

TL;DR: It is remarkable that varenicline is a potent, full agonist at α7 receptors with an EC50 of 18 ± 6 μM and an efficacy of 93 ± 7% (relative to acetylcholine).
Journal ArticleDOI

Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats

TL;DR: Depression and stress are two states during cocaine abstinence which users identify as precipitating relapse, and JDTic may have properties which attenuate both.
Journal ArticleDOI

Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor

TL;DR: A crystal structure of human KOP in complex with the potent epoxymorphinan opioid agonist MP1104 and an active-state-stabilizing nanobody is provided and key residues that propagate larger-scale structural rearrangements and transducer binding are illuminated that elucidate the structural determinants of KOP pharmacology, function, and biased signaling.